<i>Moringa oleifera </i>nanoparticles

Abstract

The Moringa oleifera nanoparticles may be synthesized by harvesting Moringa leaves, drying the Moringa leaves, powdering the dried Moringa leaves, suspending the powdered Moringa leaves in a solution, and spraying the solution into boiling water under ultrasonic conditions to obtain Moringa nanoparticles. The Moringa nanoparticles may be encapsulated by dissolving the Moringa nanoparticles and gum olibanum in ethanol to produce a mixture, injecting the inert organic phase of the mixture into an aqueous solution containing PVA, and homogenizing the aqueous solution. The Moringa nanoparticles may be useful in preventing the growth of cancer cells and in treating diabetes by inhibiting α-glucosidase and/or α-amylase activity.

Claims

1. A method of synthesizing Moringa nanoparticles, comprising: harvesting the Moringa oleifera leaves only from a Moringa oleifera tree; drying only the harvested Moringa oleifera leaves; and powdering the Moringa oleifera leaves to form the powdered Moringa oleifera leaves mixing the powdered Moringa oleifera leaves with a solvent to form a solution; spraying the solution dropwise into boiling water under ultrasonic conditions to form a mixture; stirring the resulting mixture to form the Moringa nanoparticles, wherein the nanoparticles have an average particle diameter of about 222 nm with a polydispersity of about 0.2; and encapsulating the Moringa nanoparticles in a mixture comprising gum olibanum and polyvinyl alcohol, wherein the ratio of Moringa nanoparticles:gum olibanum:polyvinyl alcohol is 1:5:7 (w/w/w).

2. The method of claim 1, wherein the leaves are obtained from a Moringa oleifera tree grown in Riyadh, Saudi Arabia.

3. The method of claim 1, wherein: 400 mg of the powdered Moringa oleifera leaves are mixed with 20 ml of the solvent; the solution is sprayed dropwise into 50 ml of boiling water at a flow rate of 0.2 ml/min for 5 minutes; and the resulting mixture is stirred at about 200-800 rpm at room temperature for about 20 minutes to form the Moringa nanoparticles.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 depicts a Zetasizer spectrum of Moringa oleifera nanoparticles.

(2) FIG. 2 depicts a Zetasizer spectrum of encapsulated Moringa oleifera nanoparticles.

(3) FIG. 3 depicts a transmission electron micrograph of Moringa oleifera nanoparticles.

(4) FIG. 4 depicts a transmission electron micrograph of Moringa oleifera nanoparticles.

(5) FIG. 5 depicts a transmission electron micrograph of encapsulated Moringa oleifera nanoparticles.

(6) FIG. 6 depicts a transmission electron micrograph of encapsulated Moringa oleifera nanoparticles.

(7) FIG. 7 depicts a graph of the cytotoxicity of Moringa oleifera nanoparticles against MCF-7 cells.

(8) FIG. 8 depicts a graph of the cytotoxicity of powdered Moringa oleifera leaves against MCF-7 cells.

(9) FIG. 9 depicts a graph of the cytotoxicity of encapsulated Moringa oleifera nanoparticles against MCF-7 cells.

(10) FIG. 10 depicts a graph of the cytotoxicity of Moringa oleifera nanoparticles against HepG-2 cells.

(11) FIG. 11 depicts a graph of the cytotoxicity of powdered Moringa oleifera leaves against HepG-2 cells.

(12) FIG. 12 depicts a graph of the cytotoxicity of encapsulated Moringa oleifera nanoparticles against HepG-2 cells.

(13) FIG. 13 depicts a graph of the anti-alpha-glucosidase inhibitory activity of Moringa oleifera nanoparticles.

(14) FIG. 14 depicts a graph of the anti-alpha-glucosidase inhibitory activity of powdered Moringa oleifera leaves.

(15) FIG. 15 depicts a graph of the anti-alpha-glucosidase inhibitory activity of encapsulated Moringa oleifera nanoparticles.

(16) FIG. 16 depicts a graph of the anti-alpha-amylase inhibitory activity of Moringa oleifera nanoparticles.

(17) FIG. 17 depicts a graph of the anti-alpha-amylase inhibitory activity of powdered Moringa oleifera leaves.

(18) FIG. 18 depicts a graph of the anti-alpha-amylase inhibitory activity of encapsulated Moringa oleifera nanoparticles.

(19) Similar reference characters denote corresponding features consistently throughout the attached drawings.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

(20) The Moringa oleifera nanoparticles may be synthesized by harvesting Moringa leaves, drying the Moringa leaves, powdering the dried Moringa leaves, suspending the powdered Moringa leaves in a solution, and spraying the solution into boiling water under ultrasonic conditions to obtain Moringa nanoparticles. In an embodiment, the Moringa oleifera leaves may be harvested from Moringa oleifera trees grown in Riyadh, Saudi Arabia. In an embodiment the powdered Moringa leaves may be suspended in an appropriate solvent, including but not limited to methanol.

(21) In an embodiment, encapsulated Moringa oleifera nanoparticles may be synthesized by harvesting Moringa leaves, drying the Moringa leaves, powdering the dried Moringa leaves, suspending the powdered Moringa leaves in a solution, spraying the solution into boiling water under ultrasonic conditions to obtain Moringa nanoparticles, dissolving the Moringa nanoparticles and gum olibanum in ethanol to produce a mixture, injecting the inert organic phase of the mixture into an aqueous solution containing PVA, and homogenizing the aqueous solution. In an embodiment, the Moringa oleifera leaves may be harvested from Moringa oleifera trees grown in Riyadh, Saudi Arabia. In an embodiment the powdered Moringa leaves may be suspended in an appropriate solvent, including but not limited to methanol. In an embodiment, the ratio of Moringa nanoparticles:gum olibanum:PVA may be 1:5:7 (w/w/w).

(22) In an embodiment, the synthesis of Moringa nanoparticles may include mixing about 400 mg of powdered Moringa oleifera leaves with about 20 ml of methanol and spraying the resulting solution into about 50 ml of boiling water dropwise at a flow rate of about 0.2 ml/min for about 5 minutes under ultrasonic conditions (ultrasonic power of 750 W and frequency of 20 kHz). The resulting solution may then be stirred at about 200-800 rpm at room temperature for about 20 minutes to produce the Moringa nanoparticles.

(23) The Moringa oleifera leaves may be powdered by any available means of rendering a dried leaf into a powder, including but not limited to grinding, blending, and other similar techniques known in the art.

(24) In an embodiment, the synthesis of encapsulated Moringa nanoparticles may include mixing about 150 mg Moringa nanoparticles with about 750 mg of gum olibanum and about 30 ml of ethanol to form a mixture, injecting the inert organic phase of the mixture into about 150 ml of an aqueous solution containing about 1,050 mg PVA, and homogenizing the resulting solution at about 22,000 rpm for about 25 minutes.

(25) In an embodiment, the Moringa nanoparticles may have an average particle diameter of about 141.6 nm with a polydispersity of about 0.32.

(26) In an embodiment, the encapsulated Moringa nanoparticles may have an average particle diameter of about 222 nm with a polydispersity of about 0.2.

(27) As used herein, the term “about,” when used to modify a numerical value, means within ten percent of that numerical value.

(28) An embodiment of the present subject matter is directed to a pharmaceutical composition comprising the Moringa nanoparticles and a pharmaceutically acceptable carrier.

(29) An embodiment of the present subject matter is directed to a method of making a pharmaceutical composition including mixing the Moringa nanoparticles with a pharmaceutically acceptable carrier. For example, the method of making a pharmaceutical composition can include mixing the Moringa nanoparticles under sterile conditions with a pharmaceutically acceptable carrier with preservatives, buffers, and/or propellants to create the pharmaceutical composition.

(30) An embodiment of the present subject matter is directed to a pharmaceutical composition including the Moringa nanoparticles. To prepare the pharmaceutical composition, the Moringa nanoparticles, as the active ingredient, are intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques. Carriers are inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorings, sweeteners, preservatives, dyes, and coatings. In preparing compositions in oral dosage form, any of the pharmaceutical carriers known in the art may be employed. For example, for liquid oral preparations, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like. Further, for solid oral preparations, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.

(31) The present compositions can be in unit dosage forms such as tablets, pills, capsules, powders, granules, ointments, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampules, auto-injector devices or suppositories, for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. The Moringa nanoparticles can be mixed under sterile conditions with a pharmaceutically acceptable carrier and, if required, any needed preservatives, buffers, or propellants. The composition can be presented in a form suitable for daily, weekly, or monthly administration. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful, suppository and the like, an amount of the active ingredient necessary to deliver an effective dose. A therapeutically effective amount of the Moringa nanoparticles or an amount effective to treat a disease, such as a bacterial infection, may be determined initially from the Examples described herein and adjusted for specific targeted diseases using routine methods.

(32) The Moringa nanoparticles can be administered to a subject in need thereof. In an embodiment, the Moringa nanoparticles can be administered to a subject in need thereof to inhibit cancer cell growth and/or prevent or treat a cancer. In a further non-limiting embodiment, the cancer can be a breast cancer or a liver cancer. In a further embodiment, the Moringa nanoparticles can be administered to a subject in need thereof to treat the effects of diabetes. In a further non-limiting embodiment, the Moringa nanoparticles can be administered to a subject in need thereof in order to inhibit the activity of at least one of α-glucosidase, α-amylase, and a combination thereof.

(33) An embodiment of the present subject matter is directed to a method of preventing cancer cell growth, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to the present subject matter.

(34) An embodiment of the present subject matter is directed to a method of inhibiting α-amylase activity, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to the present subject matter.

(35) An embodiment of the present subject matter is directed to a method of inhibiting α-glucosidase activity, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to the present subject matter.

(36) The Moringa nanoparticles or pharmaceutical compositions thereof can be administered to a subject by any suitable route. For example, the compositions can be administered orally (including bucally and sublingually), nasally, rectally, intracisternally, intra vaginally, intraperitoneally, topically, transdermally (as by powders, ointments, or drops), and/or parenterally. As used herein, “parenteral” administration refers to modes of administration other than through the gastrointestinal tract, which include intravenous, intramuscular, intraperitoneal, intrasternal, intramammary, intraocular, retrobulbar, intrapulmonary, intrathecal, subcutaneous and intraarticular injection and infusion. Surgical implantation may also be contemplated, including, for example, embedding a composition of the disclosure in the body such as, for example, in a tissue, in the abdominal cavity, under the splenic capsule, brain, or in the cornea.

(37) Accordingly, the route of administration can include intranasal administration, oral administration, inhalation administration, subcutaneous administration, transdermal administration, intradermal administration, intra-arterial administration with or without occlusion, intracranial administration, intraventricular administration, intravenous administration, buccal administration, intraperitoneal administration, intraocular administration, intramuscular administration, implantation administration, topical administration, intratumor administration, and/or central venous administration.

(38) The following examples illustrate the present subject matter.

Example 1

Synthesis of Moringa oleifera Nanoparticles

(39) Fresh Moringa leaves were collected from Moringa oleifera trees grown in Riyadh, Saudi Arabia. The leaves were air dried and powdered to form powdered Moringa oleifera leaves. 400 mg of the powdered Moringa oleifera leaves was added to 20 ml of methanol, and the resulting solution was sprayed into 50 ml of boiling water dropwise at a flow rate of 0.2 ml/min for 5 minutes under ultrasonic conditions (ultrasonic power of 750 W and frequency of 20 kHz). The contents were then stirred at 200-800 rpm at room temperature for about 20 minutes.

Example 2

Synthesis of Encapsulated Moringa oleifera Nanoparticles

(40) Encapsulated Moringa oleifera nanoparticles were synthesized using a ratio of Moringa nanoparticles:gum olibanum:PVA of 1:5:7 (w/w/w) using the nano precipitation technique as previously described (Bilati et al., 2005; Zili et al., 2005). Briefly, 150 mg of Moringa oleifera nanoparticles prepared according to Example 1 and an appropriate amount of olibanum were dissolved in 30 ml of ethanol. The internal organic phase of the resulting solution was then injected into 150 ml of an external aqueous solution containing the appropriate amount of PVA, and the solutions were homogenized at 22,000 rpm for 25 minutes.

Example 3

Characterization of Moringa oleifera Nanoparticles

(41) Dynamic light scattering (DLS) analysis on a Zetasizer (ZEN 3600, Malvern, United Kingdom) was used to observe physical characteristics of the Moringa nanoparticles and the encapsulated Moringa nanoparticles. As shown in FIG. 1 and Table 1, the Moringa nanoparticles had an average diameter of 141.6 nm with a polydispersity of 0.32 and diverse sizes. In comparison, the encapsulated Moringa nanoparticles were more monodisperse, with an average diameter of 222 nm, a polydispersity of 0.2, and diverse sizes (See FIG. 2 and Table 2).

(42) TABLE-US-00001 TABLE 1 Zetasizer results for Moringa nanopartieles Size (d.nm) % Intensity St Dev (d.nm) Z-Avg (d.nm) 141.0 Peak 1 145.8 94.9 57.33 PDI 0.324 Peak 2 19.82 5.1 4.006 Intercept 0.910 Peak 3 0.000 0.0 0.000

(43) TABLE-US-00002 TABLE 2 Zetasizer results for encapsulated Moringa nanoparticles Size (d.m) % Intensity St Dev (d.nm) Z-Avg (d.nm) 222.0 Peak 1 231.0 95.3 94.30 PDI 0.282 Peak 2 4970 4.7 626.2 Intercept 0.952 Peak 3 0.000 0.0 0.000

(44) Transmission electron microscopy (TEM) was performed using a JEM-1011 (JEOL, Japan), to study the surface morphology, shape, and size of the Moringa nanoparticles. As shown in FIGS. 3 and 4, the Moringa nanoparticles are spherical in shape with diverse sizes. As shown in FIGS. 5 and 6, the encapsulated Moringa nanoparticles are encapsulated and covered by a polymer layer.

Example 4

Evaluation of the Cytotoxic Effects of Moringa Nanoparticles Against Cancer Cells

(45) Mammalian MCF-7 cells (a human breast cancer cell line) and HepG-2 cells (a human liver cancer cell line) were obtained from the VACSERA Tissue Culture Unit. Dimethyl sulfoxide (DMSO), crystal violet, and trypan blue dye were purchased from Sigma (St. Louis, Mo., USA). Fetal Bovine Serum (FBS), Dulbecco's modified Eagle's medium (DMEM), RPMI-1640, HEPES buffer solution, L-glutamine, gentamycin and 0.25% Trypsin-EDTA were purchased from Lonza. Crystal violet stain (1%) was prepared by mixing 0.5% (w/v) crystal violet and 50% methanol, brought up to volume with ddH.sub.2O and filtered through Whatman No. 1 filter paper.

(46) MCF-7 and HepG-2 cell lines were propagated in DMEM supplemented with 10% heat-inactivated FBS, 1% L-glutamine, HEPES buffer and 50 μg/ml gentamycin. All cells were maintained at 37° C. in a humidified atmosphere with 5% CO.sub.2 and were sub-cultured two times a week.

(47) Cytotoxicity assays were performed by seeding cells from each cell line into 96-well flat-bottomed microtiter plates (Falcon, N.J., USA) at a concentration of 1×10.sup.4 cells per well in 100 μl of growth medium. Fresh medium containing different concentrations of the test sample was added after 24 hours of incubation. Specifically, serial two-fold dilutions of each sample to be tested were added to the confluent cell monolayers using a multichannel pipette. The microtiter plates were then incubated at 37° C. in a humidified incubator with 5% CO.sub.2 for a period of 48 hours. Three wells were used for each concentration of the tested samples. Control cells were incubated without adding any of the tested samples, and with or without the addition of DMSO. The percentage of DMSO present in the wells (a maximum of 0.1%) was found not to affect the experiment. After the incubation period, the respective concentrations of the sample used for each well were added to the wells once again, and the incubation was continued for a further 24 hours. Viable cells were then counted by a colorimetric method.

(48) Briefly, media was aspirated from each well and crystal violet solution (1%) was added for at least 30 minutes. The stain was then removed and the plates were rinsed with tap water to remove all excess stain. Glacial acetic acid (30%) was then added to the wells and mixed thoroughly and the absorbance was measured after gentle shaking using a Microplate reader (Tecan, Inc.) at a wavelength of 490 nm. The results were corrected for background absorbance detected in control wells without any added stain. Treated samples were then compared with stained control wells. All experiments were carried out in triplicate. The cytotoxic effect of each tested composition was calculated. Briefly, the optical density of each well was measured with a microplate reader (SunRise, Tecan, Inc., USA) to determine the number of viable cells and the percentage of viability was calculated according to Equation 1:

(49) $\left[\frac{O{D}_t}{O{D}_c}\right]\times 100\%$

(50) In Equation 1, OD.sub.t is the mean optical density of wells treated with a particular test sample and OD.sub.c is the mean optical density of untreated (control) cells. The relation between surviving cells and test sample concentration is plotted to reveal the survival curve of each tumor cell line after treatment with a particular composition. The 50% inhibitory concentration (IC.sub.50), the concentration required to cause toxic effects in 50% of intact cells, was then estimated from the graphic plots of the dose response curve using Graphpad Prism software (San Diego, Calif., USA).

(51) As illustrated in FIGS. 7-12, a significant decrease in cell survival was observed in both MCF-7 and HepG-2 cancer cell lines when treated with Moringa leaf powder, Moringa nanoparticles, and encapsulated Moringa nanoparticles. For MCF-7, an IC.sub.50 of 168±27.04 μg/ml was observed for Moringa leaf powder (M.sub.o). (See Table 4). The inhibitory activity of Moringa nanoparticles (MoN) was significantly enhanced when compared to Moringa leaf powder alone, with an IC.sub.50 of 65.6±13.97 μg/ml. (See Table 3). This inhibitory activity was further enhanced for the encapsulated Moringa nanoparticles (Mo CapN), with an IC.sub.50 of 22.5±0.63 μg/100 μl. (See Table 5) For HepG-2, an IC.sub.50 of 113.5±6.59 μg/ml was observed for Moringa leaf powder (M.sub.o). The inhibitory activity of Moringa nanoparticles (MoN) was significantly enhanced when compared to Moringa leaf powder alone, with an IC.sub.50 of 53.4±1.93 μg/ml. (See Tables 6 and 7). This inhibitory activity was further enhanced for the encapsulated Moringa nanoparticles (Mo CapN), with an IC.sub.50 of 15.2±2.37 μg/100 μl. (See Table 8). Thus, encapsulating the Moringa nanoparticles resulted in a significantly enhanced inhibitory activity against both MCF-7 and HepG-2 cancer cell lines.

(52) TABLE-US-00003 TABLE 3 Inhibitory Activity of Moringa Nanoparticles against MCF-7 (Breast Cancer) Cells (IC.sub.50 = 65.5 ± 13.97 μg/ml) Conc. Viability % (Replicates) Inhibitory (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean % S.D. ± 1000 9.75 10.86 8.61 9.74 90.26 1.13 500 17.43 19.94 18.02 18.46 81.54 1.31 250 26.81 39.75 30.89 30.15 69.85 3.04 125 35.24 40.88 41.67 39.26 60.74 3.51 62.5 48.7 48.7 54.26 50.55 49.45 3.21 31.25 73.28 19.81 74.92 76.00 24.00 3.40 15.6 89.06 94.13 89.06 90.75 9.25 2.93 7.8 97.84 99.52 96.41 97.92 2.08 1.56 3.9 100 100 99.87 99.96 0.04 0.08 2 100 100 100 100 0.00 0.00 0 100 100 100 100 0.00

(53) TABLE-US-00004 TABLE 4 Inhibitory Activity of Moringa Leaf Powder against MCF-7 (Breast Cancer) Cells (IC.sub.50 = 168 ± 27.04 μg/ml) Conc. Viability % (Replicates) Inhibitory (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean % S.D. ± 1000 16.31 14.92 13.27 14.83 85.17 1.52 500 34.67 31.83 29.4 31.97 68.03 2.64 250 42.56 45.04 40.96 42.85 57.15 2.06 125 53.24 57.35 50.67 53.75 46.25 3.37 62.5 64.39 70.21 67.95 67.85 32.15 3.06 31.25 72.16 79.48 80.23 77.29 22.71 4.46 15.6 85.24 87.31 87.31 86.62 13.38 1.20 7.8 94.06 96.28 95.34 94.23 4.77 1.11 3.9 99.71 99.71 98.26 99.23 0.77 0.84 7 100 100 100 100 0.00 0.00 0 100 100 100 100 0.00

(54) TABLE-US-00005 TABLE 5 Inhibitory Activity of Encapsulated Moringa Nanoparticles against MCF-7 (Breast Cancer) Cells (IC.sub.50 = 22.5 ± 0.63 μg/μl medium) Conc. Viability % (Replicates) Inhibitory (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean % S.D. ± 100 14.78 16.35 17.21 16.11 83.89 1.23 50 30.91 28.76 34.58 31.42 68.58 2.94 25 43.27 46.54 46.54 45.45 54.55 1.89 12.5 68.95 65.32 71.38 68.55 31.45 3.05 6.25 85.2 82.78 89.04 85.67 14.33 3.16 3.125 94.31 93.27 97.32 94.97 5.03 2.10 1.56 99.45 98.16 100 99.20 0.80 0.94 0.78 100 100 100 100 0.00 0.00 0 100 100 100 100 0.00

(55) TABLE-US-00006 TABLE 6 Inhibitory Activity of Moringa Nanoparticles against HepG-2 (Liver Cancer) Cells (IC.sub.50 = 53.4 ± 1.93 μg/ml) Conc. Viability % (Replicates) Inhibitory (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean % S.D. ± 1000 6.89 8.52 5.97 7.13 92.87 1.29 500 14.27 17.09 12.34 14.57 85.43 2.39 250 20.35 26.78 24.19 23.77 76.23 1.24 125 31.71 35.27 39.42 35.47 64.53 3.85 62.5 42.36 44.95 47.81 45.04 54.96 2.73 31.25 64.88 62.37 59.2 62.15 37.85 2.85 15.6 78.64 79.51 74.38 77.51 22.49 2.75 7.8 90.17 88.04 85.29 87.83 12.17 2.45 3.9 99.74 93.38 94.03 96.72 3.28 2.87 2 100 99.12 99.12 99.41 0.59 0.51 0 100 100 100 100 0.00

(56) TABLE-US-00007 TABLE 7 Inhibitory Activity of Moringa Leaf Powder against HepG-2 (Liver Cancer) Cells (IC.sub.50 = 113.5 ± 6.59 μg/ml) Conc. Viability % (Replicates) Inhibitory (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean % S.D. ± 1000 11.74 10.65 13.59 11.99 88.01 1.49 500 24.81 23.29 26.73 24.94 75.06 1.77 250 32.95 36.76 38.09 35.93 64.07 2.67 125 46.23 49.02 47.14 47.46 52.54 1.42 62.5 58.17 65.29 60.36 61.27 38.73 3.65 11.25 71.38 80.54 76.19 76.04 23.96 4.58 15.6 84.52 89.43 85.27 86.41 13.59 2.65 7.8 95.46 97.28 93.14 95.29 4.71 2.08 3.9 99.72 100 989.72 99.81 0.19 0.16 2 100 100 100 100 0.00 0.00 0 100 100 100 100 0.00

(57) TABLE-US-00008 TABLE 8 Inhibitory Activity of Encapsulated Moringa Nanoparticles against HepG-2 (Liver Cancer) Cells (IC.sub.50 = 15.2 ± 2.37 μg/μl medium) Conc. Viability % (Replicates) Inhibitory (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean % S.D. ± 100 12.39 10.88 13.74 12.34 87.66 1.43 50 25.28 26.94 29.43 27.22 72.78 2.09 25 36.45 38.67 41.02 38.71 61.29 2.29 12.5 49.62 53.21 56.89 53.24 46.76 3.64 6.25 74.24 76.98 82.95 78.06 21.94 4.45 3.125 89.56 91.43 95.28 92.09 7.91 2.92 1.56 96.43 98.08 99.25 97.92 2.08 1.42 0.78 99.62 100 100 99.87 0.13 0.22 0 100 100 100 100 0.00

Example 5

Evaluation of the Antidiabetic Activity of Moringa Nanoparticles

(58) Current treatments of diabetes mainly focus on reducing fluctuations in blood sugar and subsequent complications. α-amylase and α-glucosidase inhibitors are currently used for diabetic treatment as oral hypoglycemic agents. Acarbose is a commercially available enzyme inhibitor for type II diabetes. In the present study, Moringa leaves (Mo) and Moringa nano-formulations, including Moringa nanoparticles (MoN) and encapsulated Moringa nanoparticles (MoCapN) were evaluated for their inhibitory effect on α-amylase and α-glucosidase enzymes using in-vitro methods and using Acarbose as a reference anti-diabetic drug.

(59) α-glucosidase (Saccharomyces cerevisiae) and 3,5,di-nitrosalicylicacid (DNS) were purchased from Sigma-Aldrich (Bangalore). P-nitro-phenyl-α-D-glucopyranoside (p-NPG), sodium carbonate (Na.sub.2CO.sub.3), sodium dihydrogen phosphate, and di-sodium hydrogen phosphate were purchased from Hi-Media (Mumbai).

(60) The α-glucosidase and α-amylase inhibitory activity of Moringa leaf powder and Moringa nanoparticles was tested, using Acarbose as a reference drug. Briefly, α-glucosidase inhibitory activity was determined according to standard methods with minor modifications (Shai, L. J. et al., “Inhibitory effects of five medicinal plants on rat alpha-glucosidase: Comparison with their effects on yeast alpha-glucosidase,” J. Med. Plant Res. 5: pp. 2863-2867 (2011)). In a 96-well plate, a reaction mixture containing 50 μl phosphate buffer (100 mM, pH=6.8), 10 μl alpha-glucosidase (1 U/ml), and 20 μl of varying concentrations of each tested composition (1000 to 7.81 μg/ml) was preincubated at 37° C. for 15 minutes. Then, 20 μl P-NPG (5 mM) was added as a substrate and incubated for a further 20 minutes at 37° C. The reaction was stopped by adding 50 μl Na.sub.2CO.sub.3 (0.1 M). The absorbance of the released p-nitrophenol was measured at 405 nm using a Multiplate Reader. Acarbose at various concentrations (1000 to 7.81 μg/ml) was included as a standard. Control wells were maintained without adding any of the tested compositions. Each experiment was performed in triplicate. The results are expressed as percent inhibition, which was calculated using Formula 2:

(61) $\mathrm{Inhibitory}\mathrm{Activity}\%=\left(1-\frac{A_s}{A_c}\right)\times 100$

(62) Wherein A.sub.s is the absorbance of the tested composition and A.sub.c is the absorbance of the control samples. Results are expressed in terms of mean standard deviation and IC.sub.50 values were calculated using GraphPad.

(63) The α-amylase inhibitory activity of the Moringa leaf powder and the Moringa nanoparticles was also tested as previously described. Briefly, a volume of 150 μl of each composition to be tested or of the standard drug (acarbose) at concentrations varying from 2000-7.81 μg/ml was incubated with 50 μl of porcine pancreatic amylase (2 U/ml) in phosphate buffer (100 mM, pH 6.8) at 37° C. for 20 minutes in a 96-well plate. Then 100 μl of 1% starch dissolved in 100 mM phosphate buffer (pH 6.8) was further added to the reaction mixture and incubated at 37° C. for 1 hour. Dinitrosalicylate colour reagent (1 ml) was then added and boiled for 10 minutes. The absorbance of the resulting mixture was read at 540 nm and the inhibitory activity was again calculated according to Formula 2 above. All measurements were performed in triplicate and results are expressed in terms of mean±standard deviation and IC.sub.50 values were calculated using GraphPad.

(64) The inhibitory potency of Moringa leaves against α-amylase activity resulted in an IC.sub.50 value of 719.92±4.41 μg. (See Table 9 and FIG. 17). In comparison, the nano-formulations were significantly more efficacious as is evident from the IC.sub.50 values of 15.9±1.11 μg (MoN) and 94.02±1.50 μg (MoCapN). (See Tables 10 and 11 and FIGS. 16 and 18).

(65) TABLE-US-00009 TABLE 9 Anti-α-amylase Activity of Moringa Leaves Conc. Inhibitory activity (Replicates) (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean S.D. ± 1,000 54.41 53.68 54.84 54.31 0.59 500 46.38 47.12 46.36 46.62 0.43 250 31.24 32.46 31.84 31.85 0.61 125 17.63 17.24 18.94 17.94 0.89 62.5 6.35 5.84 5.98 6.06 0.26 31.25 0 0 0 0.00 0.00 15.63 0 0 0 0.00 0 7.81 0 0 0 0.00 0 0 0 0 0 0.00 0 IC.sub.50 725.40 719.5 714.62 719.72 4.41

(66) TABLE-US-00010 TABLE 10 Anti-α-amylase Activity of Moringa Nanoparticles Conc. Inhibitory activity (Replicates) (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean S.D. ± 1,000 74.35 72.16 72.79 73.10 1.13 500 68.39 68.14 66.39 67.64 1.09 250 62.31 64.32 62.31 62.98 1.16 125 52.14 53.46 52.98 52.86 0.67 62.5 34.28 32.16 32.96 33.13 1.07 31.25 21.32 20.68 20.34 20.78 0.50 15.63 19.32 18.34 18.11 18.59 0 7.81 8.39 6.99 7.68 7.66 0 0 0 0 0 0.00 0 IC.sub.50 117.51 114.8 115.69 115.9 1.11

(67) TABLE-US-00011 TABLE 11 Anti-α-amylase Activity of Encapsulated Moringa Nanoparticles Conc. Inhibitory activity (Replicates) (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean S.D. ± 195 59.37 58.31 59.06 58.91 0.55 62.5 41.08 40.31 41.39 40.93 0.56 31.25 26.31 27.81 27.33 27.15 0.77 15.63 19.42 17.98 19.25 18.88 0.67 7.81 6.35 5.91 6.22 6.16 0 3.9 0 0 0 0.00 0 1.95 0 0 0 0.00 0 0.98 0 0 0 0.00 0 0 0 0 0 0.00 0 IC.sub.50 92.98 96.14 92.95 94.0.2 1.50

(68) Further, the inhibitory potency of Moringa leaves against α-glucosidase activity demonstrated an IC.sub.50 value of 231.08±3.73 μg/m. (See Table 12 and FIG. 14). In comparison, the nano-formulations were significantly more efficacious as is evident from their IC.sub.50 values of 59.38±1.42 (MoN) and 30.13±0.83 μg (MoCapN). (See Tables 13 and 14 and FIGS. 13 and 15).

(69) TABLE-US-00012 TABLE 12 Anti-α-glucosidase Activity of Moringa Leaves Conc. Inhibitory activity (Replicates) (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean S.D. ± 1,000 60.34 61.32 58.41 60.02 1.48 500 59.31 57.11 55.71 57.44 1.80 250 51.24 51.32 50.92 51.16 1.24 125 39.84 40.13 39.25 39.74 0.45 62.5 19.68 19.14 18.32 19.05 0.68 31.25 9.35 7.31 7.89 8.18 1.05 15.63 0 0 0 0.00 0 7.81 0 0 0 0.00 0 0 0 0 0 0.00 0 IC.sub.50 236.4035 235.2547 240.1457 231.079 3.73

(70) TABLE-US-00013 TABLE 13 Anti-α-glucosidase Activity of Moringa Nanoparticles Conc. Inhibitory activity (Replicates) (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean S.D. ± 1,000 78.31 78.91 76.31 77.84 1.36 500 71.39 72.55 70.37 71.44 1.09 250 67.14 68.55 66.31 67.26 1.02 125 62.17 60.17 60.17 60.84 1.15 62.5 51.42 50.32 51.31 51.02 0.61 31.25 41.67 41.55 39.22 40.81 1.38 15.63 29.44 30.66 31.28 30.46 0 7.81 16.71 17.18 16.34 16.74 0 0 0 0 0 0.00 0 IC.sub.50 57.94872 61.35975 59.11394 59.378 1.42

(71) TABLE-US-00014 TABLE 14 Anti-α-glucosidase Activity of Encapsulated Moringa Nanoparticles Conc. Inhibitory activity (Replicates) (μg/ml) 1.sup.st 2.sup.nd 3.sup.rd Mean S.D. ± 125 76.34 77.11 74.32 75.99 1.53 62.5 62.15 66.17 63.24 63.85 2.08 31.25 51.37 54.71 50.68 52.25 2.16 15.63 20.34 22.14 21.24 21.24 0.90 7.81 12.24 12.16 12.89 12.43 0.40 3.9 8.36 7.84 8.67 8.29 0.42 1.95 0 0 0 0.00 0 0.98 0 0 0 0.00 0 0 0 0 0 0.00 0 IC.sub.50 30.57 28.99 30.89 30.13 0.83

(72) It can be concluded that, Moringa leaves and Moringa nano-formulations exhibited potent anti-cancer and anti-diabetic activities, with the Moringa nano-formulations being more effective anti-cancer agents and anti-diabetic agents, and with the encapsulated Moringa nanoparticles being even more effective than the Moringa nanoparticles alone. This could be attributed to an enhanced bioavailability of the phytochemical constituents of Moringa leaves in the nano-formulations, allowing for synergistic effects of these phytochemical constituents.

(73) It is to be understood that the encapsulated Moringa oleifera nanoparticles are not limited to the specific embodiments described above, but encompasses any and all embodiments within the scope of the generic language of the following claims enabled by the embodiments described herein, or otherwise shown in the drawings or described above in terms sufficient to enable one of ordinary skill in the art to make and use the claimed subject matter.